Related Experiment Video
Updated: Jan 19, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Integrating radiomics into clinical trial design
Jessica J Waninger1,2, Michael D Green3,4, Catherine Cheze Le Rest5
1Department of Medical Education, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Radiomics, extracting quantitative tumor features from medical images, offers non-invasive disease assessment. Standardization across radiomics processes is crucial for its integration into clinical trials and improved patient care.
Area of Science:
- Radiology
- Medical Imaging
- Oncology
Background:
- Radiomics extracts quantitative features from radiographic images to describe tumor phenotypes.
- It enables non-invasive examination of disease heterogeneity, impacting clinical trials and patient care.
Purpose of the Study:
- To review how radiomics can address challenges in clinical randomized control trials.
- To discuss difficulties in integrating robust radiomics analysis into trial design.
Main Methods:
- The review discusses the radiomics process, including image acquisition, reconstruction, segmentation, feature extraction, and computational analysis.
- Emphasis is placed on the need for standardization at each step.
Main Results:
- Standardization is essential for successful incorporation of radiomics into clinical trials.
- Addressing challenges in standardization can unlock the potential of radiomics.
Conclusions:
- Radiomics holds significant potential for clinical trials and patient care.
- Robust and repeatable radiomics analysis requires extensive standardization across all stages.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
09:09In Silico Clinical Trials for Cardiovascular Disease
10:17Guidelines and Experience Using Imaging Biomarker Explorer (IBEX) for Radiomics
Statistical Software for Data Analysis and Clinical Trials
05:16Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
